Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01488929 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia
A Phase 2 study of Schizophrenia and Cognitive Dysfunction, sponsored by Targacept.
- Completed
- Registry status
- Phase 2
- Development phase
- 603
- Enrollment target
- 20
- Study locations
NCT01488929: Completed Phase 2 study of Schizophrenia and Cognitive Dysfunction, sponsored by Targacept.
NCT01488929 is a Phase 2 study of Schizophrenia and Cognitive Dysfunction that has completed, run by Targacept. The registered enrollment target is 603 participants, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (178% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01488929, a Phase 2 study of Schizophrenia and Cognitive Dysfunction, has completed, sponsored by Targacept.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 603 participants
- Enrollment target
- 20
- Study locations
Study Summary
Negative symptoms and cognitive dysfunction in schizophrenia (CDS) are core features of schizophrenia. These negative symptoms and cognitive deficits have a devastating impact on the function, employment, and social interactions of patients with schizophrenia. Medications used to treat schizophrenia (e.g. atypical antipsychotics) do not improve negative symptoms or CDS. TC-5619 is being developed for use as an add-on therapy in combination with atypical antipsychotics to treat patients with negative symptoms and CDS.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TC-5619
Study Locations (20)
California
- Collaborative Neuroscience Network, Inc - Garden Grove
- Behavorial Research Specialists - Glendale
- Apostle Clinical Trials, Inc - Long Beach
- Synergy Clinical Research Center - National City
- Excell Research, Inc. - Oceanside
- Neuropsychiatric Research Center of Orange County - Orange
- CNRI - San Diego
Florida
- Segal Institute for Clinical Research - Lauderhill
- Compass Research, LLC - Leesburg
Missouri
- St. Charles Psychiatric Associates - Midwest Reserch Group - Saint Charles
- PsychCare Consultants Research - St Louis
New York
- Behavioral Medical Research - Brooklyn
- Finger Lakes Clinical Research - Rochester
Ohio
- Neuro-Behavorial Clinic Research, Inc. - Canton
- Midwest Clinical Research Center - Dayton
Georgia
- Atlanta Center for Medical Research - Atlanta
Illinois
- Alexian Brothers Behavioral Health Hospital - Hoffman Estates
Mississippi
- Precise Research Group - Flowood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 603 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
What the finished NCT01488929 record still lists
NCT01488929 is an interventional study that assigns participants to a tested intervention. The registered 603 participants enrollment target is mid-sized for trials with a published cap, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (178% higher).
The record links to 3 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01488929 names 20 study sites across 10 states, led by California, Florida, Missouri.
Frequently Asked Questions
What is clinical trial NCT01488929 about?
NCT01488929 is a clinical study titled "Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia". Negative symptoms and cognitive dysfunction in schizophrenia (CDS) are core features of schizophrenia. These negative symptoms and cognitive deficits have a devastating impact on the function, employment, and social interactions of patients with schizophrenia. Medications used to treat schizophrenia...
What is the current status of trial NCT01488929?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 603 participants. The study started on 2011-12. Estimated completion is 2013-11.
What conditions does trial NCT01488929 study?
This clinical trial studies the following conditions: Schizophrenia, Cognitive Dysfunction, Negative Symptoms.
What interventions are being tested in trial NCT01488929?
The interventions under investigation include: Placebo (DRUG), TC-5619 (DRUG).
Who is sponsoring clinical trial NCT01488929?
This trial is sponsored by Targacept, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01488929 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01488929's enrollment target sits among peer trials
603 27th of 315 higher than 289 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
RECRUITING · Phase 2
-
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
RECRUITING · Phase 2
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
RECRUITING · Phase 2
-
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
RECRUITING · Phase 2
-
Study of ALTO-101 in Patients With Schizophrenia
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03849443 · 604 participants · Early Phase 1
Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery
- NCT05238922 · 604 participants · Phase 1
Study of INCB123667 in Subjects With Advanced Solid Tumors
- NCT06040541 · 604 participants · Phase 1
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- NCT02342444 · 606 participants · Phase 4
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia